Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
EXEL Exelixis
17.760+0.470+2.72%
Close
02/08 16:00 ET
17.860+0.100+0.56%
Post Mkt Price 02/08 19:52 ET
High
17.930
Open
17.000
Turnover
60.74M
Low
16.990
Pre Close
17.290
Volume
3.42M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Exelixis (EXEL) Q4 Earnings Top, Revenues Beat on Cabometyx
Exelixis (NASDAQ:EXEL) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS
Exelixis (NASDAQ:EXEL – Get Rating) released its earnings results on Tuesday. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($
Barclays Sticks to Its Buy Rating for Exelixis (EXEL)
Exelixis (EXEL) Reports Q4 Loss, Tops Revenue Estimates
Analysts Conflicted on These Services Names: Exelixis (EXEL) and Cineplex (OtherCPXGF)
Exelixis Is Maintained at Overweight by Piper Sandler
Exelixis Is Maintained at Overweight by Piper Sandler
RBC Lowers Exelixis Price Target to $25 From $27, Maintains Outperform Rating
08:30 AM EST, 02/08/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Exelixis Price Target Maintained With a $24.00/Share by EF Hutton
Exelixis Price Target Maintained With a $24.00/Share by EF Hutton
Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics
Exelixis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/08/2023 38.81% EF Hutton → $24 Reiterates → Buy 01/26/2023 67.73% Credit Suisse → $29 Initiates Coverag
Company Overview
More
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
CEO： Dr. Michael M. Morrissey, PhD
Market： NASDAQ
Listing Date： 04/11/2000
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet